"Science and Technology Daily" focuses on LabMed Discovery's authoritative release of "China Hemophilia Diagnosis and Treatment Report (2024 Edition)"
image: A Model in Medical Education: Professor Wang Hongli’s Profile
Credit: LabMed Discovery Editorial Team Authors: Xue Feng, Dai Jing, Chen Lixia, Liu Wei, Zhang Houqiang, Wu Runhui, Sun Jing, Zhang Xinsheng, Wu Jingsheng, Zhao Yongqiang, Wang Xuefeng, Yang Renchi Review: Wang Hongli (Lifelong Professor of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine)
Article: "China Hemophilia Diagnosis and Treatment Report (2024 Edition)"
Journal: LabMed Discovery (English), Issue 1, 2024
Authors: Xue Feng, Dai Jing, Chen Lixia, Liu Wei, Zhang Houqiang, Wu Runhui, Sun Jing, Zhang Xinsheng, Wu Jingsheng, Zhao Yongqiang, Wang Xuefeng, Yang Renchi
Review: Wang Hongli (Lifelong Professor of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine)
As part of the Healthy China Action, the prevention and treatment of hemophilia has attracted widespread attention in China. This article systematically summarizes the current status and progress of hemophilia in the country in terms of prevalence, diagnostic technology, prevention methods, and treatment plans. Studies have shown that in terms of diagnosis, the standardization and maturity of coagulation factor activity measurement technology and genetic diagnosis technology have improved the accuracy of detection; in the field of treatment, the transition from on-demand treatment to preventive treatment has significantly reduced the annual bleeding rate of patients; in terms of new drug research and development and clinical application, the exploration of domestically produced recombinant gene products, non-factor replacement therapy drugs, and gene therapy drugs has provided patients with more choices; the progress of surgical treatment and rehabilitation treatment has also improved the quality of life of patients. However, the occurrence of inhibitors (antibodies) is still a difficult point in treatment, and further research is needed on its occurrence mechanism and intervention measures.
Overall, thanks to the attention of our government departments, the continuous efforts of medical workers, the progress of scientific research in the medical field, and the attention of many parties in society, China’s hemophilia prevention and treatment has made great progress, but there is still broad room for development in standardized management and technological innovation. In the future, we should strengthen multidisciplinary collaboration, improve the diagnosis and treatment system, and promote the diagnosis and treatment of hemophilia to develop in the direction of precision and personalization.